Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Identification and in-vitro screening of pharmacological substances for PCO-prophylaxis

Search Title by author or title

Session Details

Session Title: Presented Poster Session: PCO

Session Date/Time: Sunday 11/09/2016 | 09:30-11:00

Paper Time: 10:00

Venue: Poster Village: Pod 1

First Author: : C.Wertheimer GERMANY

Co Author(s): :    K. Eibl-Lindner   P. Pongsthorn   A. Wolf   C. Priglinger   S. Priglinger  

Abstract Details

Purpose:

Numerous pharmacologic substances have been proposed to serve for pharmacologic prophylaxis of posterior capsule opacification (PCO) in the past. However, a systemic review of published data and experimental comparison concerning safety and efficacy of the compounds is missing. Therefore, the aim of this in vitro study was to investigate the clinical potential of selected substances for PCO prophylaxis and to compare the efficacy among them.

Setting:

Laboratory for Molecular Cell Biology LMU Munich, Munich, Germany

Methods:

A Medline literature search was performed with the search terms „pharmacologic PCO prophylaxis“ and “PCO prophylaxis and pharmacology“ and more than 200 scientific publications were screened to identify pharmacologic substances which were suitable for a potential clinical application in the future. As a well-established in vitro model, FHL-124 cells were used and incubated with different concentrations of each pharmacologic substance under standard cell culture conditions. The cell number of vital cells was determined with the colorimetric ELISA test XTT (2,3-bis (2-Methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide) as described previously.

Results:

For the following substances the IC50 concentration was determined: Betamethason, Curcumine, Diclofenac, Disulfiram, Indomethacin, Lidocaine, Methotrexate, Mibefradil, Minoxidil and Prednisolone. Methotrexate und Disulfiram were the only substances to be identified with an antiproliferative effect on human lens epithelial cells. The IC50 concentrations were as follows: Disulfiram 31.5 ± 3.2 nM (R2 = 0.82) and Methotrexate 9.8 ± 1.5 nM (R2 = 0.62). No inhibition of cell proliferation was measured for Betamethasone, Indomethacin, Minoxidil, Curcumine, Diclofenac, Lidocaine, Mibefradil, and Prednisolone.

Conclusions:

In our experimental model, a direct comparison of safety and efficacy of pharmacological substances proposed for PCO prophylaxis was feasible. Disulfiram and Methotrexate were identified as most effective and less toxic compared to others ad will be further evaluated for clinical application in the future.

Financial Disclosure:

NONE

Back to previous